indirubin-3'-oxime derivative 36

**Indirubin-3'-oxime derivative 36** is a synthetic small molecule based on the indirubin-3'-oxime scaffold, designed as a potent type 1 inhibitor of FLT3, with strong antitumor activity, especially in models of acute myeloid leukemia (AML) featuring FLT3 mutations[2][6]. It shows very high inhibitory potency with IC50 values of 0.87 nM against FLT3 and 0.32 nM against the FLT3/D835Y mutant, and exhibits significant in vivo antitumor activity in mouse xenograft models when administered orally, demonstrating high oral bioavailability (42.6%)[2][6]. Mechanistically, compound 36 binds the DFG-in conformation of FLT3 kinase, in a manner comparable to approved type 1 FLT3 inhibitors such as crenolanib and gilteritinib, making it a promising candidate as an oral targeted therapy in AML[2][6].

Other names

indirubin-3'-monoxime derivative 36